Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD

Key Points

• Canada Pension Plan Investment Board acquired 55,511 ResMed shares worth approximately $10.8 million, while institutional investors collectively own 54.98% of the company.
• ResMed reported quarterly EPS of $2.95, beating estimates by $0.06, with revenue rising 8.6% year over year to $1.46 billion. The company also increased its quarterly dividend to $0.66 per share, implying a 1.1% annual yield.
• Wall Street’s consensus rating remains Hold, with seven Buy ratings and ten Holds and an average price target of $239.38. Meanwhile, company insiders sold 22,973 shares worth approximately $4.9 million over the past 90 days.

Canada Pension Plan Investment Board bought a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 55,511 shares of the medical equipment provider's stock, valued at approximately $10,818,000.

Several other hedge funds have also recently added to or reduced their stakes in RMD. International Assets Investment Management LLC bought a new stake in shares of ResMed in the 4th quarter valued at $25,000. Bell Investment Advisors Inc bought a new position in ResMed during the second quarter worth $26,000. Imprint Wealth LLC bought a new position in ResMed during the third quarter worth $26,000. WFA of San Diego LLC acquired a new position in ResMed in the second quarter valued at $26,000. Finally, Sunbelt Securities Inc. acquired a new position in ResMed in the third quarter valued at $31,000. Institutional investors own 54.98% of the company's stock.

ResMed Stock Performance

Shares of ResMed stock opened at $240.47 on Friday. ResMed Inc. has a 52 week low of $180.26 and a 52 week high of $284.87. The company has a quick ratio of 2.42, a current ratio of 3.10 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $211.81 and a 200-day moving average price of $219.18. The company has a market cap of $34.69 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.76.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. The company had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.46 billion. ResMed had a return on equity of 25.58% and a net margin of 26.94%.ResMed's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.55 earnings per share. Equities analysts anticipate that ResMed Inc. will post 12.03 earnings per share for the current fiscal year.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th will be issued a dividend of $0.66 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $2.64 dividend on an annualized basis and a yield of 1.1%. This is a positive change from ResMed's previous quarterly dividend of $0.60. ResMed's payout ratio is presently 25.31%.

Wall Street Analyst Weigh In

RMD has been the subject of a number of recent analyst reports. Citigroup reiterated a "neutral" rating and set a $235.00 price target (down from $270.00) on shares of ResMed in a report on Sunday, July 12th. Morgan Stanley reissued an "equal weight" rating and issued a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. UBS Group restated a "buy" rating and set a $300.00 target price on shares of ResMed in a research report on Tuesday, July 21st. The Goldman Sachs Group reaffirmed a "buy" rating on shares of ResMed in a research note on Wednesday, July 1st. Finally, Wells Fargo & Company lowered their target price on ResMed from $225.00 to $215.00 and set an "equal weight" rating for the company in a report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat.com, ResMed presently has an average rating of "Hold" and a consensus price target of $239.38.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $205.69, for a total value of $1,026,598.79. Following the completion of the transaction, the chief executive officer owned 466,256 shares in the company, valued at $95,904,196.64. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the sale, the director owned 52,773 shares of the company's stock, valued at $11,873,925. This trade represents a 13.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,973 shares of company stock worth $4,885,436 over the last ninety days. Insiders own 0.65% of the company's stock.

About ResMed

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source